Clinical trials recruiting in Troisdorf, Germany

Phase breakdown

Conditions recruiting in Troisdorf, Germany

Recruiting trials in Troisdorf, Germany

• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
  NCT06830720 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
  NCT05363319 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
  NCT04673955 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
  NCT06081244 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
  NCT05704829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
  NCT06102057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
  NCT05792150 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: Female
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Troisdorf, Germany?

10 recruiting trials have at least one study site in Troisdorf, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.